Rare cell multi-stage sorting microfluidic device integrating inertial and deterministic lateral displacement technology

Abstract

The invention discloses a rare cell multi-stage sorting microfluidic device integrating inertial and deterministic lateral displacement technology. The upper end of the integrated device is provided with a sample inlet, the lower part of the sample inlet is connected to a spiral channel, and the other end of the spiral channel is connected to There is a sudden expansion structure, and the other end of the sudden expansion structure is split into a first branch flow channel and a deterministic lateral displacement flow channel, and the end of the first branch flow channel is provided with a blood cell outlet; the other end of the deterministic lateral displacement flow channel is split into a second branch flow channel. The branch flow channel and the third branch flow channel, the residual blood cell outlet is provided at the end of the second branch flow channel, and the rare cell outlet is provided at the end of the third branch flow channel. The present invention makes full use of the advantages of high throughput of the inertial spiral and the high precision of the deterministic lateral displacement by integrating the inertial spiral and the deterministic lateral displacement two-stage flow channel, and achieves rare cancer treatment on the basis of simple structure through ingenious integration. The high-throughput and high-purity sorting of cells overcomes the shortcomings of existing sorting chips that are only based on a single technology and are difficult to achieve high-throughput and high-purity sorting at the same time.

Description

technical field [0001] The patent of the present invention belongs to the multi-stage sorting microfluidic device technology, and in particular relates to a microfluidic device for high-throughput and high-purity sorting of rare cell particles. Background technique [0002] Circulating tumor cells (CTCs), as seeds entering the human peripheral blood circulation, are clinically considered to be an early sign of tumor metastasis, and the detection of circulating tumor cells in blood is of great significance for the early diagnosis of cancer. The biggest challenge in the detection of CTCs is that their number is extremely rare. Usually, their ratio to normal human blood cells is only about 1:10. 9 , or only 1-100 CTCs in 1 mL of blood. Therefore, how to efficiently and accurately remove background blood cells from whole blood and capture rare circulating tumor cells is an important prerequisite for subsequent detection and analysis. Microfluidics technology, which emerged in ...

AI Technical Summary

Problems solved by technology

[0003]Although the active and passive separation technologies have made considerable progress in recent years, there are still three important indicators of purity, recovery and throughput. Their respective deficiencies, especially considering that there is generally a mutual game relationship between the three, such as the increase in flux will lead to the decrease in purity, and the recovery rate is often sacrificed in order to pursue high purity, etc., it is difficult for a single separation technology to satisfy CTCs at the same time. High-throughput, high-purity, high-recovery separation requirements

Images